NCT06348264 - Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

March 30, 2029

Study Completion Date

March 30, 2031

Conditions

Salivary Gland Neoplasm Duct

Interventions

DRUG

Rezvilutamide

Rezvilutamide 240 mg (3\*80mg tablets) will be administered orally once daily with or without food.

DRUG

Leuprolide Acetate

The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.

Trial Locations (2)

RECRUITING

Peking University First Hospital, Beijing

RECRUITING

Peking University School and Hospital of Stomatology, Beijing